


The listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A compound of formula I,



wherein

- $R^1$  and  $R^2$  are, independently of one another, hydrogen,  $C_{1-6}$  alkyl,  $OR^7$ ,  $NR^7R^8$ , CN, acyl,  $CO_2R^9$ ,  $CONR^7R^8$  or  $CSNR^7R^8$ ,
- $R^3$  is a saturated or unsaturated  $C_{1-5}$  alkylene radical, which is optionally substituted in 1 to 4 places with  $OR^7$ ,  $NR^{11}R^{12}$  or  $C_{1-4}$  alkyl ~~and in which 1 or 2  $CH_2$  groups are optionally and independently replaced by  $O$ ,  $S(O)_n$ ,  $NR^8$ ,  $=N$  or carbonyl~~, and which are optionally bridged with a methano, ethano or propano group,
- $R^4$  is  $C_{1-4}$  alkyl, substituted with  $NR^{14}R^{15}$ ,
- $R^4$  and  $R^5$  optionally together with 2 adjacent carbon atoms form a  $C_3$ - $C_4$  alkylene moiety optionally substituted in one or two places with  $NR^{14}R^{15}$ ,
- $R^5$  and  $R^6$  are, independently of one another, Hydrogen, halogen,  $OR^7$ ,  $C_{1-4}$  alkyl,  $CF_3$ , or  $OCF_3$ ,
- $R^7$ ,  $R^{18}$  and  $R^{19}$  are, independently of one another, Hydrogen,  $C_{1-6}$  alkyl or  $C_{6-10}$  aryl, which optionally is substituted with halogen or  $C_{1-4}$  alkyl,
- $R^8$ ,  $R^{11}$  and  $R^{12}$  are, independently of one another, Hydrogen,  $C_{1-6}$  alkyl,  $C_{6-10}$  aryl, which optionally is substituted with halogen or  $C_{1-4}$  alkyl,  $COR^{10}$ ,  $CO_2R^{10}$ ,  $CONR^{18}R^{19}$  or  $CSNR^{18}R^{19}$ ,

$R^9, R^{10}$

and  $R^{20}$  are, independently of one another,  $C_{1-6}$  alkyl or  $C_{6-10}$  aryl, which optionally is substituted with halogen or  $C_{1-4}$  alkyl,

$R^{14}$  and  $R^{15}$  are, independently of one another, Hydrogen,  $CO_2R^{20}$  or  $C_{1-6}$  alkyl, which optionally is substituted with halogen, hydroxy,  $C_{1-4}$  alkoxy, nitro, amino,  $C_{1-6}$  alkyl, trifluoromethyl, carboxyl, cyano, carboxamido,  $C_{3-7}$  cycloalkyl, indanyl, 1,2,3,4-tetrahydronaphthyl,  $C_{6-10}$  aryl, wherein the aryl radical is optionally substituted with halogen, hydroxy,  $C_{1-4}$  alkoxy,  $C_{1-4}$  alkyl,  $CF_3$ ,  $NO_2$ ,  $NH_2$ ,  $N(C_{1-4} \text{ alkyl})_2$  or carboxyl, or

$R^{14}$  and  $R^{15}$  —optionally together with the nitrogen atom form imidazole, indole, isooxazole, isothiazole, furan, oxadiazole, oxazole, pyrazine, pyridazine, pyrimidine, pyridine, pyrazole, pyrrole, tetrazole, thiazole, triazole, thiophene, thiadiazole, benzimidazole, benzofuran, benzoxazole, isoquinoline, quinoline, furanyl, thienyl, piperidine, pyrrolidine, morpholine, thiomorpholine, hexahydroazepine, piperazine, N-methyl piperazine, 2,6-dimethylmorpholine, phenylpiperazine, 4-(4-fluorobenzoyl) piperidine, or indazole, and

n is 0, 1 or 2,

or a tautomeric or isomeric form or a salt of a compound of formula I.

2. (Previously Amended) A compound according to claim 1, in which  $R^3$  is a  $C_{1-5}$  alkylene radical, which is optionally bridged with a methano, ethano or propano group.

3. (Previously Amended) A compound according to claim 1, in which  $R^1$  and  $R^2$  is hydrogen.


4-5. (Cancelled)

6. (Previously Amended) A pharmaceutical composition comprising an effective amount of a compound according to claims 1, and a pharmaceutically acceptable vehicle or adjuvant.

7. (Previously Amended) A process for the preparation of a pharmaceutical composition comprising combining an effective amount of at least one compound according to claim 1, and at least one solid, liquid or semi-liquid excipient or auxiliary and, optionally, one or more other active compounds.


8-9. (Cancelled)

10. (Currently Amended) A process for ~~the preparation of~~ preparing a compound according to claim 1, comprising reacting ~~wherein~~ a compound of formula (IIa) or (IIb) or it's a salt thereof



IIa

or



IIb

wherein

R<sup>3</sup> to R<sup>6</sup> are as defined in claim 1,

R is methyl or ethyl, and


X is O or S,

~~is reacted~~ with ammonia, a primary or secondary amine, hydroxylamine ~~and/or its derivatives,~~ or hydrazine ~~and/or its derivatives,~~ and followed by optionally ~~then the separating~~ isomers are ~~separated and the salts are formed~~ or forming a salt.

11-14. (Cancelled)

15. (Previously Amended) A method for inhibiting neuronal NDS, comprising administering an effective amount of a compound according to claim 1 or a composition containing said compound to a patient in need thereof.

16. (Currently Amended) A compound of formula I,



wherein

- $R^1$  and  $R^2$  are, each independently, hydrogen or  $C_{1-6}$  alkyl,
- $R^3$  is a saturated or unsaturated  $C_{1-5}$  alkylene radical, which is optionally substituted in 1 to 4 places with  $OR^7$ ,  $NR^{11}R^{12}$  or  $C_{1-4}$  alkyl and in which 1 or 2  $CH_2$  groups are optionally and independently replaced by  $O$ ,  $S(O)_n$ ,  $NR^8$ ,  $=N$  or carbonyl, and which are optionally bridged with a methano, ethano or propano group,
- $R^4$  is  $C_{1-4}$  alkyl, substituted with  $NR^{14}R^{15}$ ,
- $R^4$  and  $R^5$  optionally together with 2 adjacent carbon atoms form a  $C_3$ - $C_4$  alkylene moiety optionally substituted in one or two places with  $NR^{14}R^{15}$ ,
- $R^5$  and  $R^6$  are, independently of one another, Hydrogen, halogen,  $OR^7$ ,  $C_{1-4}$  alkyl,  $CF_3$ , or  $OCF_3$ ,
- $R^7$ ,  $R^{18}$  and  $R^{19}$  are, independently of one another, Hydrogen,  $C_{1-6}$  alkyl or  $C_{6-10}$  aryl, which optionally is substituted with halogen or  $C_{1-4}$  alkyl,
- $R^8$ ,  $R^{11}$  and  $R^{12}$  are, independently of one another, Hydrogen,  $C_{1-6}$  alkyl,  $C_{6-10}$  aryl, which optionally is substituted with halogen or  $C_{1-4}$  alkyl,  $COR^{10}$ ,  $CO_2R^{10}$ ,  $CONR^{18}R^{19}$  or  $CSNR^{18}R^{19}$ ,

R<sup>9</sup>, R<sup>10</sup>

and R<sup>20</sup> are, independently of one another, C<sub>1-6</sub> alkyl or C<sub>6-10</sub> aryl, which optionally is substituted with halogen or C<sub>1-4</sub> alkyl,

R<sup>14</sup> and R<sup>15</sup> are, independently of one another, Hydrogen, CO<sub>2</sub>R<sup>20</sup> or C<sub>1-6</sub> alkyl, which optionally is substituted with halogen, hydroxy, C<sub>1-4</sub> alkoxy, nitro, amino, C<sub>1-6</sub> alkyl, trifluoromethyl, carboxyl, cyano, carboxamido, C<sub>3-7</sub> cycloalkyl, indanyl, 1,2,3,4-tetrahydronaphthyl, C<sub>6-10</sub> aryl, wherein the aryl radical is optionally substituted with halogen, hydroxy, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkyl, CF<sub>3</sub>, NO<sub>2</sub>, NH<sub>2</sub>, N(C<sub>1-4</sub> alkyl)<sub>2</sub> or carboxyl, or

*E2*  
*Cont*

~~R<sup>14</sup> and R<sup>15</sup> — optionally together with the nitrogen atom form imidazole, indole, isooxazole, isothiazole, furan, oxadiazole, oxazole, pyrazine, pyridazine, pyrimidine, pyridine, pyrazole, pyrrole, tetrazole, thiazole, triazole, thiophene, thiadiazole, benzimidazole, benzofuran, benzoxazole, isoquinoline, quinoline, furanyl, thienyl, piperidine, pyrrolidine, morpholine, thiomorpholine, hexahydroazepine, piperazine, N-methyl-piperazine, 2,6-dimethylmorpholine, phenylpiperazine, 4-(4-fluorobenzoyl)-piperidine, or indazole, and~~

n is 0, 1 or 2,

or a tautomeric or isomeric form or a salt of a compound of formula I.

17. (Previously Presented) A compound according to claim 16, wherein R<sup>3</sup> is a C<sub>1-5</sub> alkylene radical, which is optionally bridged with a methano, ethano or propane group.

18. (New) A method for treating amyotrophic lateral sclerosis, comprising administering an effective amount of a compound according to claim 1 or a composition containing said compound to a patient in need thereof.

---